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Although glucocentric therapies may improve glycaemic control (as determined by glycated haemoglobin levels), evidence suggests that this approach alone has limited beneficial effects on CV outcomes relative to improvements in lipid and blood pressure control. This may be explained in part by the fact that current antidiabetic treatment regimens primarily address overall glycaemia and/or fasting plasma glucose, but not the postprandial plasma glucose (PPG) excursions that have a fundamental causative role in increasing CV risk. This literature review evaluates the relationship between PPG and the risk of CV disease, discusses the treatment of T2DM with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and examines the associated CV outcomes. The literature analysis suggests that exaggerated PPG excursions are a risk factor for CV disease because of their adverse pathophysiologic effects on the vasculature, resulting in increased all-cause and CV-related mortality. Although GLP-1 RAs are well established in the current T2DM treatment paradigm, a subgroup of these compounds has a particularly pronounced, persistent and short-lived effect on gastric emptying and, hence, lower PPG substantially. However, current long-term data on CV outcomes with GLP-1 RAs are contradictory, with both beneficial and adverse effects having been reported. This review explores the opportunity to direct treatment towards controlling PPG excursions, thereby improving not only overall glycaemic control but also CV outcomes. 1,2 CV disease remains the most common cause of death among adults with T2DM, 2 and the concurrence of CV disease in patients with T2DM results in a poorer prognosis compared with individuals with CV disease alone. 2 Hence, a better understanding of the pathophysiology of vascular changes that underlie this relationship, and how best to address them, is likely to improve outcomes.
Several large studies have evaluated the relationship between glycaemic control with different treatment regimens and CV disease in individuals with T2DM. The 10-year follow-up to the United Kingdom Prospective Diabetes Study (UKPDS) found that intensive treatment of T2DM with sulphonylurea, insulin or metformin lowered the patient's risk of myocardial infarction (MI) as well as the risks of diabetes-related death and all-cause mortality vs conventional therapy (dietary restrictions). 3, 4 Individually, most other studies have shown a limited ability of current glucocentric therapies to have a discernible and favourable impact on CV disease. [5] [6] [7] [8] [9] [10] However, a metaanalysis of data from the UKPDS, combined with those of 3 other large randomized studies, 11 found an overall 9% reduction in the risk of major CV events, mostly resulting from a 15% reduction in MI risk, for more-vs less-intensive glucose-control treatment regimens.
Furthermore, there was a trend towards reduction in CV disease in individuals without previously reported CV events. Another systematic review of these same studies found that intensive vs conventional glucose control reduced the risk of certain CV outcomes, largely nonfatal MI, but not the risk of CV death or all-cause mortality. 12 Similarly, a separate meta-analysis of data from these same 4 studies and another showed that intensive vs standard glycaemic control significantly reduced coronary events, but again, with no significant effect on all-cause mortality. Of note, although these analyses demonstrated that intensive glucose therapy and the resulting improved glycaemic control may reduce the risk of CV disease, hyperglycaemia is a weaker risk factor for CV disease than cholesterol or blood pressure. Hence, the relative impact of reducing hyperglycaemia on CV outcomes is less than the adequate control of these other concurrent risk factors. 13 Nevertheless, many studies have implied that postprandial plasma glucose (PPG) is a powerful and independent risk factor for CV disease, 14 with the development of atherosclerosis having been described much earlier as a postprandial phenomenon. 15 Glycaemic control is assessed predominantly using 3 measurements: primarily glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG), and rarely PPG. Considering that most individuals spend the majority of the day in the postprandial and postabsorptive states (approximately 21 hours per day) rather than the fasting state (3 hours per day, at the end of the night), 16 the predominance of the PPG state within the daily metabolic cycle makes it an important target for the improvement of overall glycaemic control.
The current T2DM treatment paradigm comprises various drug classes and allows for individualization of therapy to control FPG and PPG based on patients' needs, disease characteristics and preferences. 17 As part of this paradigm, 1 class of injectable therapy is the glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Since approval of the first of these compounds in 2006, these agents have enabled further tailoring of treatment to each patient. 18 The potential relationship between amplified PPG and CV disease has been a focus of research in T2DM for a number of years, and interventional trials have gone 1 step further by trying to control PPG and, as a result, reduce the risk of CV events and slow T2DM
progression. The present review aims to evaluate the relationship between PPG and CV risk, and discuss the effects of treatment with the GLP-1 RAs, which appear to reduce CV risk in individuals with T2DM. The sodium-glucose cotransporter-2 (SGLT-2) inhibitors, particularly empagliflozin, also appear to lower CV risk in patients with T2DM. 19, 20 In contrast, the dipeptidyl peptidase-4 (DPP-4) inhibitors 21 and insulin therapy 22 do not affect the risk of CV disease in this population. While the CV effects of all of these drug classes warrant detailed discussion, the present review will focus on the GLP-1 RAs. 23, 24 In response to acute hyperglycaemia, gene expression relating to free radical scavenging (detoxification) is downregulated in human skeletal muscle and adipose tissue. 32 A study of healthy male volunteers aimed to mimic the blood glycaemic parameters of poorly controlled patients with T2DM, and demonstrated that acute hyperglycaemia released free radicals, altered baroreflex activity and increased blood pressure and heart rate. 33 Considered together, these observations support the hypothesis that oxidative stress is a major pathophysiologic mechanism responsible for the development of CV disease in patients with T2DM.
| CELLULAR AND VASCULAR EFFECTS OF ELEVATED PPG LEVELS
In addition, acute hyperglycaemia in healthy volunteers results in activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 34 a protein complex involved in stress responses that is linked to cancer and inflammatory diseases. Several other studies involving individuals with diabetes have shown that hyperglycaemia can activate the transcription of NF-κB-regulated inflammatory genes. 35 In a cross-sectional study of 232 Japanese patients with T2DM, exaggerated PPG excursions were independently correlated with the presence of microangiopathy in the form of diabetic retinopathy and neuropathy. 36 Moreover, development and progression of macrovascular disease and atherosclerosis and, indeed, the 2-hour PPG level, have been found to be significant determinants of carotid intimamedia thickness (CIMT, a measure of atherosclerosis) and shown to be more closely correlated with CIMT than FPG in patients with T2DM and in subjects with normal glucose tolerance. 37 Exaggerated PPG excursions reportedly also decrease vasodilation, 38 resulting in an increase in the sheer force on the vascular endothelium resulting from reduced blood flow and increased blood pressure.
| EXAGGERATED PPG: AN INDEPENDENT RISK FACTOR FOR CV DISEASE AND ALL-CAUSE AND CV-RELATED MORTALITY
Endothelial dysfunction, including reduced vasodilation, and increased oxidative stress predict CV events in patients with documented CV disease. 39 Table 1 summarizes the findings of several observational studies that demonstrated the association between PPG and development of CV disease in non-diabetic subjects and patients with T2DM. Moreover, these studies indicated that a high PPG level is also an independent predictor of all-cause mortality and death resulting from CV disease. This finding appears to be consistent across both sexes and across multiple races.
| POTENTIAL FOR REDUCING CV EVENTS BY CONTROLLING PPG EXCURSIONS
Despite the evidence of an association between PPG and CV risk, reports on the possible effects of treatment that lower PPG on CV outcomes are inconclusive and conflicting. In subjects with impaired glucose tolerance, treatment with acarbose slowed the progression of CIMT reduction compared with placebo. 52 Furthermore, treatment with meglitinides, a class of short-acting oral antidiabetics that increases insulin secretion in a manner similar to sulphonylureas, and 40 Hoorn study: an 8-year follow-up of a populationbased cohort of more than 2300 older (50-75 years) subjects
All-cause and CV mortality were predicted by increased 2-h PPG Based on a subset of 6394 non-diabetic subjects, those with the most extreme PPG excursions 1 h after a 50 g glucose challenge had a significantly increased risk of fatal coronary disease compared with individuals with lower PPG excursions Nakagami (2004) 44 Analysis of 5 studies of a total of more than 6800 subjects of Japanese and Asian Indian origin in patients with T2DM who had experienced an acute MI. 60 As PPG excursions were improved in patients treated with prandial insulin compared with those receiving basal insulin only, and total glucose exposure was similarly improved in both arms, 60 one would expect the incidence of CV events to have been lower in the prandial vs basal insulin group. However, the risk of CV events was not reduced in either treatment group and, as a result, the study was halted prematurely. 60 A subsequent post hoc analysis of this study did show a beneficial effect of reducing PPG on CV risk in older individuals. 61 A feasible explanation for the absence of difference between the 2 treatment groups in the original HEART2D study may be the fact that both groups were treated with insulin, as insulin itself exerts a powerful inhibitory effect on activation of oxidative stress. Table 2 .
A recent head-to-head comparison 65 assessed the effects on PPG and gastric emptying of 2 GLP-1 RAs, short-acting lixisenatide and long-acting liraglutide. As expected, based on previous reports that the predominant effect of lixisenatide is to delay gastric emptying, leading to reduced glucose reabsorption and subsequent reductions in PPG, 66, 67 lixisenatide achieved greater reductions than did liraglutide in both area under the curve PPG 0030-0430 h and gastric emptying (P < .001 for both, for lixisenatide vs liraglutide). Surprisingly, FPG was unchanged for both treatments. This study also evaluated 24-hour heart rate, and showed differences between the 2 short-and long-acting agents. 65 
| ACCELERATED HEART RATE WITH GLP-1 RAS AND ASSOCIATED RISK
Current literature suggests that an increase in heart rate of 10 bpm leads to at least a 20% higher risk of cardiac death, and that this elevated CV risk is similar to that associated with a 10 mm Hg increase in systolic blood pressure. 68 A large prospective cohort study has
shown that an elevated resting heart rate (RHR) is a strong risk factor for the development of fatal MI; compared with a RHR of <60 bpm, a RHR of >90 bpm is associated with a 2-and 3-fold higher risk of CV death in men and women, respectively. 69 Also, in a study involving patients with T2DM with a high RHR, there was a greater incidence or progression of nephropathy and retinopathy, 70 and an increased risk of all-cause mortality, CV death and major CV outcomes. 71 As noted above, published data indicate that GLP-1 RAs can influence heart rate, although the extent of this increase varies among medications. A recent analysis assessing the impact of lixisenatide, exenatide, liraglutide, albiglutide, exenatide long-acting release and dulaglutide on heart rate showed that, in patients with T2DM, prandial GLP-1 RAs led to a modest and transient increase in mean 24-h heart rate, whereas the long-acting GLP-1 RAs caused a more profound increase. 72 When patients with T2DM were further assessed using 24-hour ambulatory heart rate monitoring, 8 weeks of treatment with liraglutide (1.2 or 1.8 mg) resulted in a clinically significant increase in 24-hour mean heart rate of 9 bpm (P < .0001 vs baseline) compared with an increase of 3 bpm with lixisenatide 20 μg. 65 Moreover, the increase in heart rate with liraglutide was predominantly at night, abolishing the normal circadian rhythm in heart rate, which is reduced overnight. In a manner similar to lixisenatide, exenatide twice daily resulted in an insignificant 2 bpm increase in 24-hour mean heart rate in a 12-week interventional study, and also maintained the natural circadian rhythm in heart rate. 73 Hence, some evidence suggests that any potentially adverse increases in heart rate appear to be limited to the long-acting GLP-1 RAs. The precise mechanism by which these drugs affect heart rate is unknown, although a study employing a murine model found that the GLP-1 receptor is central in the control of heart rate. 74 mice vs those injected with saline. 87 Furthermore, liraglutide was also seen to reduce cardiac rupture and infarct size and to improve cardiac output. 87 However, the Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) study showed that liraglutide treatment vs placebo was not associated with improved clinical stability following hospitalization in subjects with advanced heart failure and reduced left ventricular ejection fraction, both with and without diabetes. . This showed that lixisenatide was non-inferior to placebo (P < .001) but was not superior (P = .81).
| CV OUTCOMES WITH GLP-1 RAS
There were no differences in the rates of hospitalizations for heart failure or rates of death between the lixisenatide and placebo groups.
Overall, the study showed that the addition of once-daily lixisenatide to the antidiabetic treatment regimen did not significantly impact on the rate of major CV events or other related serious adverse events in patients with acute coronary syndrome. Therefore, noting the spe- 
| CONCLUDING REMARKS
Our analysis of current literature suggests that poor glycaemic control, and especially excessive glycaemic excursions predominantly after meals (PPG), may increase the risk of CV disease in patients with T2DM and individuals with normal glucose tolerance. [40] [41] [42] [43] [44] [45] [49] [50] [51] However, the relationship between postprandial glucose hyperglycaemia and CV outcomes is complex, with additional research needed to characterize this association further.
In order to achieve HbA1c targets in patients with T2DM, individualized treatment that controls both PPG and FPG may be the best option, 95 with antidiabetic medications that control PPG being of particular interest because of the role of PPG excursions in the pathophysiology of CV disease. In order to maintain a patient-centred, individualized approach to treatment, the respective distribution of postprandial and basal therapies should be modulated according to each patient's 24-hour glycaemic profile. While this procedure is usually recommended for choosing the optimum pre-meal time at which boluses of rapid-acting insulin should be injected during implementation of a basal-plus insulin regimen, we believe that it is useful for a similar system to be implemented for treatment regimens involving basal insulin plus a short-acting GLP-1 RA, such as lixisenatide.
As discussed, the approved GLP-1 RAs have varying effects; some specifically control PPG, while others target FPG (Table 2) . Hence, the use of prandial GLP- that a more individualized approach may be justified.
In conclusion, exaggerated PPG excursions appear to have a fundamental causative role in the relationship between T2DM and increased CV risk. This finding presents an opportunity to direct treatment towards also controlling PPG excursions, to improve both glycaemic control and also CV outcomes.
